Civica Rx (Civica, Inc.) today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway.
Merck has completed the acquisition of US-based biopharmaceutical company ArQule in a deal valued at around $2.7bn.
Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a collaboration with Schrödinger, a company focused on transforming the way therapeutics are discovered with a physics-based computational platform, to bring the two companies’ technology platforms together to discover new antibody therapeutics against G-protein coupled receptor (GPCR) targets.
Astellas Pharma has signed a deal worth up to $897.5m with Adaptimmune Therapeutics to co-develop and co-commercialise stem-cell derived allogeneic CAR-T and TCR T-cell therapies for cancer.
BioMotiv, a mission-driven biopharma company, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, today announced a strategic collaboration to co-develop therapies.
Charles River announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company.
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals and Gemphire Therapeutics closed on December 31, 2019.
Eli Lilly has agreed to acquire US-based biopharmaceutical company Dermira in an all-cash transaction valued at around $1.1bn.
Gilead Sciences announced that the company has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074.
Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, together with the existing management team has acquired Ardena, a specialist contract development and manufacturing organization (CDMO) focused on early phase drug development, from Mentha Capital.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.